A Phase 1/2 interventional study of brentuximab vedotin and bendamustine in Hodgkin Disease, sponsored by Seagen Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-12.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 38th largest by enrollment, is one of 10 that started in 2013, is one of 12 in phase 1/2, and was the 22nd registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 10 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
22 studies in Hodgkin Disease by Pfizer: none open now, none under way, none of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 22 studies in Hodgkin Disease by Pfizer, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2013, is one of 3 in phase 1/2, and was the 13th registered.
Pfizer’s Hodgkin Disease studies by the year they started, since 2000.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Pfizer’s 22 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stage study designed to determine the recommended dose level of bendamustine in combination with brentuximab vedotin. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles
Drug: brentuximab vedotin · Drug: bendamustine
1.8 mg/kg every 3 weeks by intravenous (IV) infusion
Also known as: Adcetris; SGN-35
90 mg/m2 on Days 1 and 2 of 3-week cycles
Complete Remission Rate
Complete remission rate among all subjects (Phase 1 and 2 combined) treated at the dose level selected for Phase 2. Complete remission (CR) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma is a disappearance of all evidence of disease.
Time frame: Up to 4.6 months
Incidence of Adverse Events (AEs)
All AEs reported after initiation of treatment and pre-existing conditions that worsen after initiation of treatment will be considered treatment-emergent AEs (TEAEs). All AEs will be coded by system organ class, MedDRA preferred term, and severity grade using NCI CTCAE V4.03. All recorded AEs will be included in the data listings.
Time frame: Up to 13.8 months
Incidence of Dose-limiting Toxicities
Incidence of dose-limiting toxicity (DLT) was evaluated in an initial safety cohort of 10 patients who were followed for protocol-defined DLT events until Cycle 2 Day 1.
Time frame: Up to 3 weeks; first cycle of therapy through the first day of Cycle 2
Overall Best Response Rate
Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease), partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites), stable disease (SD, failure to obtain a complete or partial response or progressive disease), or progressive disease (PD, any new lesion or increase by 50% or more of previously involved sites from nadir) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma
Time frame: Up to 4.6 months
Duration of Response
The time from first observation of remission to disease progression/relapse or death from any cause, whichever occurs first.
Time frame: Up to 47.8 months
Progression-free Survival
The time from first dose of study medication to first documentation of disease progression/relapse, or to death due to any cause, whichever occurs first.
Time frame: Up to 49 months
June 2013 - July 2016
| Milestone | Brentuximab Vedotin + Bendamustine |
|---|---|
| Started | 55 |
| Completed ≥2 cycles of combo treatment | 53 |
| Completed 16 cycles of bv treatment | 17 |
| Completed | 0 |
| Not completed | 55 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Study termination by sponsor | 42 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Death | 5 |
Complete remission rate among all subjects (Phase 1 and 2 combined) treated at the dose level selected for Phase 2. Complete remission (CR) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma is a disappearance of all evidence of disease.
| percentage of participants | Brentuximab Vedotin + Bendamustine |
|---|---|
| Complete Remission Rate | 73.6 (59.67 to 84.74) |
All AEs reported after initiation of treatment and pre-existing conditions that worsen after initiation of treatment will be considered treatment-emergent AEs (TEAEs). All AEs will be coded by system organ class, MedDRA preferred term, and severity grade using NCI CTCAE V4.03. All recorded AEs will be included in the data listings.
| Participants | Brentuximab Vedotin + Bendamustine |
|---|---|
| Any Treatment-Emergent Adverse Event (TEAE) | 55 |
| Any TEAE with Severity >= Grade 3 | 31 |
| Any Treatment-Related Adverse Event | 54 |
| Any Serious Adverse Event | 18 |
| Any Treatment-Related Serious Adverse Event | 15 |
| Treatment Discontinuation Due to Adverse Event | 20 |
Incidence of dose-limiting toxicity (DLT) was evaluated in an initial safety cohort of 10 patients who were followed for protocol-defined DLT events until Cycle 2 Day 1.
| Participants | Brentuximab Vedotin + Bendamustine |
|---|---|
| Incidence of Dose-limiting Toxicities | 0 |
Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease), partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites), stable disease (SD, failure to obtain a complete or partial response or progressive disease), or progressive disease (PD, any new lesion or increase by 50% or more of previously involved sites from nadir) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma
| Participants | Brentuximab Vedotin + Bendamustine |
|---|---|
| Complete Remission | 39 |
| Partial Remission | 10 |
| Stable Disease | 3 |
| Progressive Disease | 1 |
The time from first observation of remission to disease progression/relapse or death from any cause, whichever occurs first.
| months | Brentuximab Vedotin + Bendamustine |
|---|---|
| Duration of Response | 43.0 (18.7 to 47.8) |
The time from first dose of study medication to first documentation of disease progression/relapse, or to death due to any cause, whichever occurs first.
| months | Brentuximab Vedotin + Bendamustine |
|---|---|
| Progression-free Survival | 44.2 (20.9 to 49.0) |
Collected over Up to 13.8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brentuximab Vedotin + Bendamustine | 5/55 (9.1%) | 18/55 (32.7%) | 55/55 (100%) |
| Event | Brentuximab Vedotin + Bendamustine |
|---|---|
| PyrexiaGeneral disorders | 8/55 |
| HypotensionVascular disorders | 5/55 |
| ChillsGeneral disorders | 3/55 |
| MalaiseGeneral disorders | 2/55 |
| DiarrhoeaGastrointestinal disorders | 2/55 |
| NauseaGastrointestinal disorders | 2/55 |
| VomitingGastrointestinal disorders | 2/55 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 2/55 |
| UrticariaSkin and subcutaneous tissue disorders | 2/55 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/55 |
| Event | Brentuximab Vedotin + Bendamustine |
|---|---|
| NauseaGastrointestinal disorders | 40/55 |
| FatigueGeneral disorders | 30/55 |
| DiarrhoeaGastrointestinal disorders | 20/55 |
| VomitingGastrointestinal disorders | 20/55 |
| ConstipationGastrointestinal disorders | 17/55 |
| ChillsGeneral disorders | 15/55 |
| PyrexiaGeneral disorders | 15/55 |
| AlopeciaSkin and subcutaneous tissue disorders | 14/55 |
| RashSkin and subcutaneous tissue disorders | 14/55 |
| Peripheral sensory neuropathyNervous system disorders | 14/55 |
All subjects who enrolled and received at least 1 dose of brentuximab vedotin.
| Age, Categorical(Participants) | Brentuximab Vedotin + Bendamustine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 50 |
| >=65 years | 5 |
| Age, Continuous(years) | Brentuximab Vedotin + Bendamustine |
|---|---|
| Median | 36 (19 to 79) |
| Sex: Female, Male(Participants) | Brentuximab Vedotin + Bendamustine |
|---|---|
| Female | 31 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | Brentuximab Vedotin + Bendamustine |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 51 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Brentuximab Vedotin + Bendamustine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 46 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(participants) | Brentuximab Vedotin + Bendamustine |
|---|---|
| United States | 55 |
| Eastern Cooperative Group Oncology Performance Status(Participants) | Brentuximab Vedotin + Bendamustine |
|---|---|
| 0 | 31 |
| 1 | 23 |
| 2 | 1 |
The record gives a start of Jun 2013, a primary completion of Dec 2015 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brentuximab Vedotin · Bendamustine